Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study

• Published in: Leukemia & lymphoma Vol. 63; no. 13; pp. 3063 - 3071
• Main Authors: Stamatoullas, Aspasia, Ghesquières, Hervé, Feugier, Pierre, André, Marc, Le Bras, Fabien, Gac, Anne-Claire, Borel, Cécile, Gastinne, Thomas, Quittet, Philippe, Morschhauser, Franck, Ribrag, Vincent, Guidez, Stephanie, Nicolas-Virelizier, Emmanuelle, Berriolo-Riedinger, Alina, Vander Borght, Thierry, Edeline, Véronique, Brice, Pauline
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 10.11.2022
• Series: Leukemia & lymphoma
• Subjects: Antineoplastic Combined Chemotherapy Protocols - adverse effects; autologous stem cell transplantation; brentuximab vedotin; Brentuximab Vedotin - therapeutic use; Carboplatin - therapeutic use; Etoposide - therapeutic use; Hodgkin Disease - drug therapy; Hodgkin lymphoma; Humans; ICE regimen; Ifosfamide - therapeutic use; Immunoconjugates - therapeutic use; Life Sciences; Lymphoma - drug therapy; Neoplasm Recurrence, Local - drug therapy; refractory; relapse; salvage chemotherapy; Treatment Outcome; refractory; salvage chemotherapy; relapse; autologous stem cell transplantation; Hodgkin lymphoma; ICE regimen; brentuximab vedotin
• ISSN: 1042-8194; 1029-2403; 1029-2403
• DOI: 10.1080/10428194.2022.2107204

This phase I/II study assessed the combination of brentuximab vedotin (BV) with ifosfamide-carboplatin-etoposide (ICE) as a second-line therapy in refractory/relapsed (R/R) classical Hodgkin lymphoma (cHL) patients. Phase I study was designed to determine the maximum tolerated dose (MTD) of BV (10 patients) and phase II evaluated the rate of complete metabolic response (CMR) after 2 cycles of BV-ICE (42 patients). There were no dose-limiting toxicities (DLT) during phase I recommending BV 1.8 mg/kg for phase II. Twenty-six patients (61.9%) achieved CMR after 2 cycles of BV-ICE and 37 patients (88%) were transplanted. With a median follow-up of 38 months, the 3-year progression free survival (PFS) and overall survival (OS) rate were 64.3% and 100%, respectively. Hematological toxicities (81%) and infections (21%) were the most frequent adverse event encountered BV-ICE regimen is feasible with manageable toxicities and could be an alternative to other salvage treatments. Trial Registration: ClinicalTrials.gov identifier: NCT02686346